LIPO-Liposome Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : LIPO-Liposome

LIPO 0.309

0.0%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: G-MAN who wrote (801)	9/9/1999 8:12:00 AM
From: Daniel Levy	of 900

Puck, excellent review! One point that you didn't make however: If Evacet proves efficacious with limited toxicity at lower doses, I would predict trials of the low-dose drug in women with only clinically apparent local disease. That's the current use of Tamoxifen (Which, in fact, has significant potential toxicity in the long term - read uterine cancer.) Throughout my training (I'm an MD), we were taught that breast cancer is a systemic disease, and that without some sort of systemic approach to treatment, recurrences would be common and predictable. A drug with limited toxicity that was helpful against tumor cells that weren't clinically apparent yet would be a Godsend.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next